Overall Fundamental outlook

Business Operations:

Sector: Basic Materials
Industry: Agricultural Inputs

Bayer CropScience Limited engages in the manufacture, sale, and distribution of insecticides, fungicides, herbicides, and various other agrochemical products and corn seeds in India, Germany, Bangladesh, and internationally. It provides medicines primarily in the therapeutic areas of cardiology, gynecology, diabetes, oncology, and ophthalmology; and computed tomography, X-Ray, and magnetic resonance imaging devices. In addition, the company offers consumer health products that are used as a daily health solution to treat minor illnesses, as well as sells and distributes hybrid seeds, such as corn and paddy. Further, it provides digital farming products comprising FarmRise and other digital applications, such as drones for spray services, etc., as well as provides various technologies, such as remote sensing, IoT sensors, GPS, artificial intelligence, and data analytics to monitor and manage crop growth, soil quality, weather patterns, and other factors. The company also exports its products. Bayer CropScience Limited was founded in 1863 and is based in Thane, India.

Revenue projections:

Revenue projections for BAYERCROP
Revenue projections for BAYERCROP

With BAYERCROP's revenues expected to fall below the previous year's, investors are likely to approach the stock with caution. Declining revenues can negatively affect profitability, which makes it harder for the company to maintain investor confidence and perform well in the market.

Financial Ratios:

currentRatio 1.916000
forwardPE 21.677214
debtToEquity 2.758000
earningsGrowth 0.131000
revenueGrowth 0.051000
grossMargins 0.404850
operatingMargins 0.150160
trailingEps 153.220000
forwardEps 193.276690

Bayer CropScience Limited's current ratio being 1.916 suggests the company will have no issues paying off its short-term debt. With sufficient cash reserves and current assets, Bayer CropScience Limited can easily cover its immediate liabilities, reflecting solid financial health.
Bayer CropScience Limited's Forward PE being in a good range indicates the stock is priced well relative to its earnings. It is not overvalued, leaving space for future growth, making it an appealing option for investors interested in long-term value appreciation.
Bayer CropScience Limited's forward EPS is higher than its trailing EPS, suggesting the company is expected to improve its profitability this financial year. This reflects growing confidence in Bayer CropScience Limited's earnings potential, with forecasts indicating better financial performance than in the prior year.

Price projections:

Price projections for BAYERCROP
Price projections for BAYERCROP

BAYERCROP's current valuation relative to projections shows a lack of distinct risks or opportunities. This neutral stance may lead investors to take a more conservative approach, maintaining their current positions until new information becomes available.

Recommendation changes over time:

Recommendations trend for BAYERCROP
Recommendations trend for BAYERCROP


A recent buy bias from analysts toward BAYERCROP indicates strong confidence in the stock's future performance. This could encourage investors to park their money in BAYERCROP, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.